CABALETTA BIO, INC. (CABA): Price and Financial Metrics
GET POWR RATINGS... FREE!
CABA Stock Price Chart Interactive Chart >
CABA Price/Volume Stats
| Current price | $0.64 | 52-week high | $14.95 |
| Prev. close | $0.65 | 52-week low | $0.59 |
| Day low | $0.64 | Volume | 402,800 |
| Day high | $0.68 | Avg. volume | 565,967 |
| 50-day MA | $1.13 | Dividend yield | N/A |
| 200-day MA | $1.87 | Market Cap | 18.63M |
CABALETTA BIO, INC. (CABA) Company Bio
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
Latest CABA News From Around the Web
Below are the latest news stories about CABALETTA BIO INC that investors may wish to consider to help them evaluate CABA as an investment opportunity.
Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines ConferencePHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 4:00 p.m. ET in New York, NY. A live webcast of the presentati |
Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV CongressPHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data through 6 months of follow-up in cohorts A1 through A4 as well as 28-day safety data and DSG3-CAART persistence data through day 29 for cohorts A1 through A5 from the DesCAARTes™ trial at the 31st European Academy |
Cabaletta Bio to Participate in Upcoming Investor Conferences in SeptemberPHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September: Morgan Stanley 20th Annual Global Healthcare Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, |
Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ TrialPHILADELPHIA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present new clinical and translational data from cohort A4 and safety data from cohort A5 in the DesCAARTes™ trial of DSG3-CAART in a late-breaking oral presentation at the upcoming 31st European Academy of Dermatology and Venereology (EADV) |
Analysts Offer Insights on Healthcare Companies: Freeline Therapeutics Holdings (FRLN), Cabaletta Bio (CABA) and Neovasc (NVCN)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Freeline Therapeutics Holdings (FRLN – Research Report), Cabaletta Bio (CABA – Research Report) and Neovasc (NVCN – Research Report) with bullish sentiments. Freeline Therapeutics Holdings (FRLN) H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Freeline Therapeutics Holdings today and set a price target of $15.00. The company's shares closed last Friday at $0.95, close to its 52-week low of $0.65. According to TipRanks. |
CABA Price Returns
| 1-mo | -35.99% |
| 3-mo | -50.00% |
| 6-mo | -68.32% |
| 1-year | -94.58% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -83.11% |
| 2021 | -69.63% |
| 2020 | -10.67% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...